Oncolytics Biotech announces issuance of 27th U.S. patent
news-medical.net     May 21, 2008            

Oncolytics Biotech Inc. today announced that it has been granted U.S. Patent 7,374,752 entitled "Reovirus for the Treatment of Cellular Proliferative Disorders." The claims cover pharmaceutical compositions which comprise various recombinant reoviruses. "This patent provides the Company with... [read full story]                    


View all news articles about*:
Biotech Biotechnology Corporate Industrial Intellectual Issues Legal Oncolytics Patents Pharmaceuticals Property
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies

View other selected articles:

Oncolytics initiates US Phase II lung cancer trial

pharmaceutical-business-review.com     Sep 3, 2008   5 related          

Oncolytics Biotech has announced that following the FDA review, the company is initiating a US Phase II clinical trial using intravenous administration of Reolysin in combination with paclitaxel and carboplatin in patients...                    

comments

US NCI initiates Phase II enrollment for Reolysin

pharmaceutical-business-review.com     Aug 16, 2008   4 related          

Oncolytics Biotech has announced that the US National Cancer Institute, part of the National Institutes of Health, has started enrollment in a Phase II clinical trial for patients with metastatic melanoma using systemic...                    

comments

U.S. NCI Starts Enrolment In Phase 2 Systemic Melanoma Clinical Trial With REOLYSIN(R)

medicalnewstoday.com     Aug 13, 2008   9 related          

Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced that the U.S. National Cancer Institute (NCI), part of the National Institutes of Health, has started enrolment in a Phase 2 clinical trial for patients...                    

comments

U.S. Patent Disclosures

tmcnet.com     Jul 31, 2008          

of Halle, Germany, received U.S. Patent No. 7,371,404, titled "Amphoteric liposomes and their use." Oncolytics Biotech Inc., of Calgary, Alberta, was granted U.S. Patent No. 7,374,752, titled "Reovirus for the Treatment of...                    

comments